Correction noted and I recall that. Your 10k notes

Correction noted and I recall that. Your 10k notes the upfront payment was received and there’s no guarantee that they will move forward with development of the vaccine. So I’m looking forward to hearing about progress there whether “material” or simply informing of progress. And it’s common sense that once your bc vaccine is refocused on a smaller market then that overall value changes. I understand about 3+ and Herceptin and did talk with Craig about that in 2011 or so when the company made changes in an effort to bring in more lower her2 expressing patients. I wrote that yesterday here. Anyway, while the p value wasn’t met it was of course because those patients get Herceptin as I’ve said as well numerous times. The beauty is that dfs for the AE arm in 3+ was in line with what was found for Herceptin in a large study (link). But we’re still targeting a subgroup of that wider market as of this stage of development.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...ort=reader